baha the information company

baha is a leading provider of real-time market data, financial news, technology and solutions for the financial industry. baha offers real-time data terminals for professionals, global financial market data covering over 12 million financial instruments on more than 150 exchanges, as well as 24/7 breaking news with global coverage and free web and mobile apps. From a total of around 200 real-time data providers worldwide, only Reuters 1851, Bloomberg 1981 and now baha in 2021 were named after the founder.

DZ Bank Knock-Out REGN/ DE000DJ7M726 /

16.12.2024 11:37:20	Изменение-	Бид22:00:31	Предложение22:00:31	Базовый актив	Цена исполнения	Дата истечения	Тип опциона
4.95EUR	-	- Величина цены спроса: -	- Величина цены предложения: -	Regeneron Pharmaceut...	1,247.9658 -	31.12.2078	Put

GlobeNewswire 26.08.2024 Ordspono™ (odronextamab) Approved in the European Union for the Treatment of Relapsed/Refractory Fol...

GlobeNewswire 26.08.2024 Latest Dupixent® (dupilumab) and Itepekimab Data at ERS Highlight Scientific Innovation and Leadersh...

GlobeNewswire 21.08.2024 Regeneron Provides Update on Biologics License Application for Linvoseltamab

GlobeNewswire 07.08.2024 Regeneron Announces Investor Conference Presentations and Oncology Investor Webcast

GlobeNewswire 01.08.2024 Regeneron Reports Second Quarter 2024 Financial and Operating Results

GlobeNewswire 31.07.2024 Regeneron Announces the 2024 Winners of the Regeneron Prize for Creative Innovation

GlobeNewswire 03.07.2024 Dupixent® (dupilumab) Approved in the European Union as the First-ever Targeted Therapy for Patients...

GlobeNewswire 28.06.2024 Odronextamab Recommended for EU Approval by the CHMP to Treat Relapsed/Refractory Follicular Lymphom...

GlobeNewswire 27.06.2024 Regeneron to Report Second Quarter 2024 Financial and Operating Results and Host Conference Call and...

GlobeNewswire 26.06.2024 Dupixent® (dupilumab) Positive Phase 3 Data in Children 1 to 11 Years of Age with Eosinophilic Esoph...

GlobeNewswire 16.06.2024 Updated Linvoseltamab Data Showcase Continued Deepening of Responses in Patients with Heavily Pre-Tr...

GlobeNewswire 11.06.2024 Kevzara® (sarilumab) Approved by FDA for the Treatment of Active Polyarticular Juvenile Idiopathic A...

GlobeNewswire 31.05.2024 Dupixent® (dupilumab) Recommended for EU Approval by the CHMP to Treat Patients with COPD

GlobeNewswire 31.05.2024 Update on FDA Priority Review of Dupixent® (dupilumab) for the Treatment of COPD Patients with Type ...

GlobeNewswire 23.05.2024 Promising Anti-tumor Activity of Novel Costimulatory Bispecific Antibody REGN7075 (EGFRxCD28) in Com...

GlobeNewswire 20.05.2024 Dupixent® (dupilumab) Late-Breaking Data from NOTUS Confirmatory Phase 3 COPD Trial Presented at ATS...

GlobeNewswire 17.05.2024 More than $9 Million Awarded to High School Scientists and Engineers at the Regeneron International ...

GlobeNewswire 13.05.2024 Dupixent® (dupilumab) sBLA Accepted for FDA Priority Review for Treatment of Adolescents with Chroni...

GlobeNewswire 08.05.2024 Latest DB-OTO Results Show Dramatically Improved Hearing to Normal Levels in a Child with Profound G...

GlobeNewswire 06.05.2024 Regeneron Announces Investor Conference Presentations

GlobeNewswire 02.05.2024 Regeneron Reports First Quarter 2024 Financial and Operating Results

GlobeNewswire 29.04.2024 EYLEA® HD (aflibercept) Injection 8 mg Presentations at ARVO Reinforce Sustained and Clinically Mean...

GlobeNewswire 25.04.2024 Regeneron and Mammoth Biosciences Collaborate to Pursue Next-Generation CRISPR-Based Gene Editing fo...

GlobeNewswire 24.04.2024 Regeneron to Showcase Progress in Advancing Novel Investigational Treatment Approaches for a Broad R...

GlobeNewswire 22.04.2024 Regeneron to Highlight Advances in Genetic Medicine Research at American Society of Gene and Cell Th...

DZ Bank Knock-Out REGN/ DE000DJ7M726 /

Если вы хотите получить ответ на свой отзыв, укажите, пожалуйста, адрес своей электронной почты.